JP7021107B2 - パモ酸ピルビニウム及びその結晶形態の調製方法 - Google Patents
パモ酸ピルビニウム及びその結晶形態の調製方法 Download PDFInfo
- Publication number
- JP7021107B2 JP7021107B2 JP2018553220A JP2018553220A JP7021107B2 JP 7021107 B2 JP7021107 B2 JP 7021107B2 JP 2018553220 A JP2018553220 A JP 2018553220A JP 2018553220 A JP2018553220 A JP 2018553220A JP 7021107 B2 JP7021107 B2 JP 7021107B2
- Authority
- JP
- Japan
- Prior art keywords
- crystal form
- formula
- pamoate
- pyruvinium
- form iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1cc2ccccc2c(Cc2c(cccc3)c3cc(*)c2O)c1O Chemical compound *c1cc2ccccc2c(Cc2c(cccc3)c3cc(*)c2O)c1O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
IR(ATR、cm-1):1616,1585、及び1571(芳香族)、1374,1354,1228,及び1057(CH3O-SO3-)、1012,707
MS:382(M+)
1H NMR(300MHz、DMSO):8.50(d、J=9Hz、1H、CHH(22))、8.42(d、J=9Hz、1H、CHH(23))、8.21(d、J=9Hz、1H、CHH(18))、8.06(d、J=15Hz、1H、CHH(14)またはHC(15))、7.57(m、4H、CHH(11)+H(19)+H(10)+H(12))、7.35(d、J=6Hz、2H、CHH(9)+H(13))、7.20(j、J=2,7Hz、1H、CHH(21))、7.19(d、J=15Hz、1H、CHHC(15)又はH(14))、6.72(s、1H、CHHC(4))、4.35(s、3H、CH3MeSO4 -又はH(26))、3.37(s、3H、CH3H(26)又はMeSO4 -)、3.09及び3.02(s、6H CH3H(27)+H(28))、2.23(s、3H、CH3H(6)又はH(7))、2.00(s、3H、CH3H(7)又はH(6))。
MS:382.3(M+)
1H-NMR(300MHz、DMSO)δ(ppm):8.49(d、J=9Hz、2H、H22)、8.43(d、J=9Hz、2H、H23)、8.12(2d、J=10Hz、4H、H18、H37)、8.10(s、2H、H33)、8.08(d、J=15Hz、2H、H15)、7.6-7.4(m、10H、H10、H11、H12、H19、H34)、7.37-7.34(2d、4H、H9、H13)、7.21(d、J=15Hz、2H H14)、7.20(s、2H、H21)、7.06(m、2H、H36)、6.96(m、2H、H35)、6.72(s、2H、H4)、4.64(s、2H、H29(CH2))、4.34(s、6H、H26(CH3))、3.08(s、12H、H27及びH28(CH3)、2.23(s、6H、H7(CH3)、2.00(s、6H、H6(CH3))。
Claims (16)
- 前記工程が塩基の存在下で行われる、請求項1に記載の方法。
- 前記塩基がアンモニアである、請求項2に記載の方法。
- 前記式(II)の化合物と前記式(III)の化合物とのモル比が1.33~2.00である、請求項1~3のいずれかに記載の方法。
- 前記方法が水とC1-C4アルコールとの混合物の存在下で実施され、次に前記方法が、CuKα線(1.5418A)を用いたX線回折計で測定して6.0、8.6、9.5、10.3、10.5、14.3、14.9、16.6、17.4、18.1、19.1、19.7、20.6,21.5,22.0,22.6,23.6、及び24.9±0.2度2θに特徴的なピークを含むX線回折図を有する、前記式(I)のピルビニウムパモ酸塩の結晶形態IIIをもたらす、請求項1~4のいずれかに記載の方法。
- 前記工程a)が、C1-C4炭化水素、C3-C6環状エーテル、C1-C3アルキル-COO-C1-C4アルキル、ハロ-C1-C4-炭化水素、及びそれらの混合物で構成される群から選択される溶媒の存在下で実施され、
前記工程b)が、C1-C4アルコール、C3-C6環状エーテル、C1-C3アルキル-COO-C1-C4アルキル、及びそれらの混合物で構成される群から選択される溶媒の存在下で実施される、
請求項6に記載の方法。 - 前記工程a)がトルエンの存在下で実施され、
前記工程b)がメタノールの存在下で実施される、
請求項6~7のいずれか1項に記載の方法。 - 前記工程b)の塩基がピペリジンである、請求項6~8のいずれか1項に記載の方法。
- CuKα線(1.5418A)を用いたX線回折計で測定して2.8,5.1,7.2,8.9,9.6,9.9,15.9,16.3,17.9,21.0±0.2度2θに特徴的なピークを含むX線回折図を有する、式(I)のピルビニウムパモ酸塩の結晶形態Aの調製方法であって、
(c)CuKα線(1.5418A)を用いたX線回折計で測定して6.0、8.6、9.5、10.3、10.5、14.3、14.9、16.6、17.4、18.1、19.1、19.7、20.6,21.5,22.0,22.6,23.6、及び24.9±0.2度2θに特徴的なピークを含むX線回折図を有する、前記式(I)のピルビニウムパモ酸塩の結晶形態IIIを、還流温度で結晶形態IIIを結晶形態Aに変換するのに必要な時間、エタノールでスラリー化する工程と、
(d)20℃~30℃で冷却する工程と、
を含む、方法。 - 前記工程(c)が1~5時間実施される、請求項10に記載の式(I)のピルビニウムパモ酸塩の結晶形態Aの調製方法。
- CuKα線(1.5418A)を用いたX線回折計で測定して6.0、8.6、9.5、10.3、10.5、14.3、14.9、16.6、17.4、18.1、19.1、19.7、20.6,21.5,22.0,22.6,23.6、及び24.9±0.2度2θに特徴的なピークを含むX線回折図を有する、式(I)のピルビニウムパモ酸塩の結晶形態IIIの調製方法であって、
(g)前記式(I)のピルビニウムパモ酸塩の結晶形態Aを、還流温度で前記結晶形態Aを前記結晶形態IIIに変換するのに必要な時間、水とエタノールとの混合物でスラリー化する工程と、
(h)前記工程(g)で得られた前記結晶形態IIIを、90℃~95℃で分離させる工程と、
(i)前記工程(h)で得られた前記結晶形態IIIを、最初に90℃~95℃の熱水で洗浄し、次にエタノールで洗浄する工程と
を含む、方法。 - 請求項10~11のいずれかに記載の方法によって結晶形態IIIから式(I)のピルビニウムパモ酸塩の結晶形態Aを調製する工程と、次いで、請求項12に記載の方法によって結晶形態Aを結晶形態IIIに変換する工程と、を含む、CuKα線(1.5418A)を用いたX線回折計で測定して6.0、8.6、9.5、10.3、10.5、14.3、14.9、16.6、17.4、18.1、19.1、19.7、20.6,21.5,22.0,22.6,23.6、及び24.9±0.2度2θに特徴的なピークを含むX線回折図を有する、式(I)のピルビニウムパモ酸塩の結晶形態IIIの精製方法。
- 1種以上の薬学的に許容される賦形剤又は担体と共に、請求項14~15のいずれかにおいて定義された式(I)のピルビニウムパモ酸塩の結晶のいずれかを含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382169.7 | 2016-04-13 | ||
EP16382169.7A EP3231796A1 (en) | 2016-04-13 | 2016-04-13 | A process for the preparation of pyrvinium pamoate and crystalline forms thereof |
PCT/EP2017/058773 WO2017178524A1 (en) | 2016-04-13 | 2017-04-12 | A process for the preparation of pyrvinium pamoate and crystalline forms thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019511523A JP2019511523A (ja) | 2019-04-25 |
JP2019511523A5 JP2019511523A5 (ja) | 2020-05-21 |
JP7021107B2 true JP7021107B2 (ja) | 2022-02-16 |
Family
ID=55809063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018553220A Active JP7021107B2 (ja) | 2016-04-13 | 2017-04-12 | パモ酸ピルビニウム及びその結晶形態の調製方法 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP3231796A1 (ja) |
JP (1) | JP7021107B2 (ja) |
BR (1) | BR112018071009A2 (ja) |
ES (1) | ES2689371B1 (ja) |
FI (1) | FI3442956T3 (ja) |
WO (1) | WO2017178524A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220409611A1 (en) * | 2019-10-22 | 2022-12-29 | Thomas Jefferson University | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008527047A (ja) | 2005-01-18 | 2008-07-24 | イミューソル インコーポレイテッド | 新規キノリニウム塩及び誘導体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2515912A (en) * | 1946-10-01 | 1950-07-18 | Eastman Kodak Co | Pyrrole dimethinecyanine dyes |
BE572031A (ja) | 1957-11-06 |
-
2016
- 2016-04-13 EP EP16382169.7A patent/EP3231796A1/en not_active Withdrawn
-
2017
- 2017-03-29 ES ES201700479A patent/ES2689371B1/es active Active
- 2017-04-12 BR BR112018071009-1A patent/BR112018071009A2/pt active Search and Examination
- 2017-04-12 EP EP17717678.1A patent/EP3442956B1/en active Active
- 2017-04-12 FI FIEP17717678.1T patent/FI3442956T3/fi active
- 2017-04-12 WO PCT/EP2017/058773 patent/WO2017178524A1/en active Application Filing
- 2017-04-12 JP JP2018553220A patent/JP7021107B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008527047A (ja) | 2005-01-18 | 2008-07-24 | イミューソル インコーポレイテッド | 新規キノリニウム塩及び誘導体 |
Non-Patent Citations (1)
Title |
---|
高田則幸,創薬段階における原薬Formスクリーニングと選択,PHARM STAGE,Vol.6, No.10,2007年01月15日,p.20-25 |
Also Published As
Publication number | Publication date |
---|---|
ES2689371A1 (es) | 2018-11-13 |
JP2019511523A (ja) | 2019-04-25 |
EP3442956B1 (en) | 2024-03-27 |
EP3231796A1 (en) | 2017-10-18 |
FI3442956T3 (fi) | 2024-05-03 |
ES2689371B1 (es) | 2019-08-22 |
WO2017178524A1 (en) | 2017-10-19 |
EP3442956A1 (en) | 2019-02-20 |
BR112018071009A2 (pt) | 2019-02-12 |
ES2689371A8 (es) | 2018-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3765448A1 (en) | New polymorphs and new path to synthesize tafamidis | |
US8501960B2 (en) | Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof | |
US11739057B2 (en) | Polymorphic forms of Belinostat and processes for preparation thereof | |
US9695159B2 (en) | Process for preparation of canagliflozin | |
EA034409B1 (ru) | Способы получения кристаллического фенилацетата l-орнитина | |
US11168047B2 (en) | Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol | |
CA3034606A1 (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
EP2601175A1 (en) | A novel crystalline compound comprising saxagliptin and phosphoric acid | |
EP2311794B1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium polymorphs | |
US9932321B2 (en) | Process for the preparation of piperidine compounds | |
CN111072572B (zh) | Elagolix关键中间体的硫酸氢盐的晶型及其制备和应用 | |
JP7021107B2 (ja) | パモ酸ピルビニウム及びその結晶形態の調製方法 | |
KR20220008285A (ko) | 디아미노피리미딘 화합물의 염, 이의 고체, 이의 제조 방법 및 이의 용도 | |
US20140128444A1 (en) | Novel crystalline salts of asenapine with organic di-acids and tri-acids | |
RU2228931C2 (ru) | Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида | |
JPH0357895B2 (ja) | ||
JPS5849369A (ja) | 新規のイミダゾール化合物 | |
US20210323929A1 (en) | Purified Detomidine, Process of Preparing and Methods of Use | |
RU2599788C2 (ru) | Новая полиморфная форма кальцимиметического соединения | |
TWI797249B (zh) | 新生黴素(novobiocin)類似物及脯胺酸之共晶型、其製造方法及用途 | |
WO2020178847A1 (en) | Cocrystal of roxadustat and d-proline | |
OA12665A (en) | New anhydrous crystalline forms of gabapentin. | |
US9920045B2 (en) | Solid state forms of a PDE10 inhibitor | |
US20210040069A1 (en) | DACOS Type NNRTIS Amino Acid Ester Derivative, Preparation Method Thereof, Pharmaceutical Composition, and Application Thereof | |
US11111208B2 (en) | Process for the preparation of safinamide mesylate intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200408 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200408 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7021107 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |